Deutsche Bank raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $18 from $16 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright
- Avadel Pharmaceuticals Reports Strong Q2 Growth
- Avadel Pharmaceuticals reports Q2 EPS 10c, consensus 3c
- Avadel Pharmaceuticals sees FY25 revenue $265M-$275M, consensus $260.01M
- Avadel Pharmaceuticals sees Q3 revenue $71M-$75M, consensus $70.61M